摘要
目的研究转录因子Sp1在胰腺导管腺癌组织中的表达特征,并探讨其表达对胰腺导管腺癌患者预后的影响。方法采用免疫组织化学技术检测60例胰腺导管腺癌组织Sp1的表达情况,分析该因子的表达与胰腺导管腺癌患者预后的关系。结果Sp1在胰腺导管腺癌组织中的阳性表达率为75%(45/60),伴有门静脉侵犯和神经侵犯患者Sp1阳性表达明显高于不伴有门静脉侵犯和神经侵犯患者,而Sp1的阳性表达和肿瘤的部位、分化程度、淋巴结转移、是否伴有十二指肠侵犯及肿瘤分期无明显相关。Sp1阳性组患者中位生存期12个月,Sp1阴性组患者中位生存期19个月,Sp1阴性组患者生存期长于Sp1阳性组生存期,有显著性差异。结论Sp1在胰腺导管腺癌中呈过度表达和活化,Sp1对胰腺导管腺癌侵犯门静脉和胰周神经具有提示作用,是一个预后不良的指标。
Objective To study the expression of transcriptional factor Sp1 in human pancreatic ductal carcinoma tissues and its prognostic significance. Methods Expression of Sp1 in 60 pancreatic ductal carcinoma cases with various clinical pathologic characteristics was detected by using immunohistochemistry. The significance of Sp1 expression on the survival of patients was evaluated. Results The positive expression rate of Sp1 in 60 pancreatic ductal carcinoma cases was 75% （45/60）. In patients with portal vein and peripheral nerve invasion the positive rate of Sp1 expression was significantly higher than that in those without portal vein and peripheral nerve invasion. Expression of Sp1 had no relation with the location and differentiation of tumor, lymph metastasis, duodenum invasion and TNM stage. The medium survival time was 19 months in patients with negative Sp1 expression and 12 months for positive Sp1 expression tumor which was statistically significant. Conclusion Sp1 is over expressed in pancreatic ductal carcinoma and might be served as an independent prognostic factor in pancreatic ductal carcinoma.
出处
《同济大学学报（医学版）》
CAS
2009年第3期5-8,共4页
Journal of Tongji University(Medical Science)
关键词
转录因子SP1
胰腺肿瘤
免疫组织化学
transcription factor Sp1
pancreatic cancer
immunohistochemistry
